Eagle Pharmaceuticals (NASDAQ:EGRX)‘s stock had its “underperform” rating reiterated by analysts at Mizuho in a research note issued to investors on Wednesday, MarketBeat Ratings reports. They presently have a $40.00 price objective on the specialty pharmaceutical company’s stock, up from their prior price objective of $37.00. Mizuho’s price target would suggest a potential downside of 26.58% from the stock’s current price.

A number of other equities research analysts have also issued reports on EGRX. BidaskClub raised Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, December 2nd. ValuEngine lowered Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Zacks Investment Research lowered Eagle Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 9th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $79.00 target price on shares of Eagle Pharmaceuticals in a research report on Tuesday, January 30th. Finally, Royal Bank of Canada set a $71.00 target price on Eagle Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, February 26th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $63.33.

How to Become a New Pot Stock Millionaire

Shares of EGRX stock traded up $0.28 during trading on Wednesday, hitting $54.48. The stock had a trading volume of 50,434 shares, compared to its average volume of 251,731. The firm has a market capitalization of $778.47, a price-to-earnings ratio of 16.54 and a beta of 1.32. The company has a quick ratio of 3.88, a current ratio of 3.99 and a debt-to-equity ratio of 0.24. Eagle Pharmaceuticals has a 12 month low of $45.05 and a 12 month high of $97.15.

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its earnings results on Monday, February 26th. The specialty pharmaceutical company reported $0.84 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.00 by ($0.16). The company had revenue of $46.80 million for the quarter, compared to analyst estimates of $53.65 million. Eagle Pharmaceuticals had a return on equity of 34.16% and a net margin of 21.94%. The firm’s revenue for the quarter was down 42.3% on a year-over-year basis. During the same period last year, the firm earned $3.52 earnings per share. equities analysts anticipate that Eagle Pharmaceuticals will post 2.57 earnings per share for the current fiscal year.

In related news, Director Sander A. Flaum sold 2,340 shares of the company’s stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $53.94, for a total transaction of $126,219.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 19.50% of the stock is currently owned by insiders.

A number of large investors have recently bought and sold shares of EGRX. Smith Asset Management Group LP acquired a new position in Eagle Pharmaceuticals during the fourth quarter valued at $187,000. Municipal Employees Retirement System of Michigan raised its position in Eagle Pharmaceuticals by 68.1% during the third quarter. Municipal Employees Retirement System of Michigan now owns 3,210 shares of the specialty pharmaceutical company’s stock valued at $191,000 after buying an additional 1,300 shares during the period. Campbell Newman Asset Management Inc. acquired a new position in Eagle Pharmaceuticals during the fourth quarter valued at $200,000. MetLife Investment Advisors LLC acquired a new position in Eagle Pharmaceuticals during the fourth quarter valued at $218,000. Finally, Schroder Investment Management Group acquired a new position in Eagle Pharmaceuticals during the third quarter valued at $219,000.

TRADEMARK VIOLATION NOTICE: This story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.watchlistnews.com/eagle-pharmaceuticals-egrx-price-target-raised-to-40-00-at-mizuho/1956549.html.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.